Vorsetuzumab mafodotin was evaluated in a phase I dose-escalation study in patients with R/R CD70-positive lymphomas or metastatic renal cell carcinoma (RCC) without sufficient activity to support further clinical development (NCT01015911) [170]. The gene discussed is CD70; the disease is lymphoma.